Early detection of lung cancer by using an autoantibody panel in Chinese population. (1st February 2018)

• Record Type: Journal Article
• Authors: Ren, Shengxiang; Zhang, Shucai; Jiang, Tao; He, Yayi; Ma, Zhiyong; Cai, Hourong; Xu, Xiaohong; Li, Yan; Cai, Weijing; Zhou, Jing; Liu, Xiaopeng; Hu, Xuejun; Zhang, Jun; Yu, Hui; Zhou, Caicun; Hirsch, Fred R.
• Is Part Of: Oncoimmunology. Volume 7:Number 2(2018)
• Publication Date: 2018-02-01
• Subjects: Lung cancer -- Biomarker -- Autoantibody -- Tumor-associated antigen -- Early detection; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2017.1384108
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: We have previously identified a panel of autoantibodies (AABs), including p53, GAGE7, PGP9.5, CAGE, MAGEA1, SOX2 and GBU4-5, that was helpful in the early diagnosis of lung cancer. This large-scale, multicenter study was undertaken to validate the clinical value of this 7-AABs panel for early detection of lung cancer in a Chinese population. Two independent sets of plasma samples from 2308 participants were available for the assay of AABs (training set = 300; validation set = 2008). The concentrations of AABs were quantitated by enzyme-linked immunosorbent assay (ELISA), and the optimal cutoff value for each AAB was determined in the training set and then applied in the validation set. The value of the 7-AABs panel for the early detection of lung cancer was assessed in 540 patients who presented with ground-glass nodules (GGNs) and/or solid nodules. In the validation set, the sensitivity and specificity of the 7-AABs panel were 61% and 90%, respectively. For stage I and stage II non-small cell lung cancer (NSCLC), the sensitivity of the 7-AABs panel was 62% and 59%, respectively, and for limited stage small cell lung cancer (SCLC) it was 59%; these sensitivity values were considerably higher than for traditional biomarkers (including CEA, NSE and CYFRA21-1). Importantly, the combination of the 7-AABs panel and low-dose computed tomography (CT) scanning significantly improved the diagnostic yield in patients presenting with GGNs and/or solid nodules. In conclusion, our 7-AABs panel has clinical value for early detection of lung cancer, including early-stage lung cancer presenting as GGNs.